Crossmark

Population Pharmacodynamic Modeling of Eflornithine-Based Treatments Against Late-Stage Gambiense Human African Trypanosomiasis and Efficacy Predictions of L-eflornithine-Based Therapy

Crossref DOI link: https://doi.org/10.1208/s12248-022-00693-2

Published Online: 2022-03-25

Published Print: 2022-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Amilon, Carl

Boberg, Mikael https://orcid.org/0000-0002-4422-6226
Tarning, Joel

Äbelö, Angela

Ashton, Michael

Jansson-Löfmark, Rasmus
License Information

Text and Data Mining valid from 2022-03-25

Version of Record valid from 2022-03-25
More Information

Article History

Received: 25 November 2021

Accepted: 21 February 2022

First Online: 25 March 2022

Declarations

:

: Although co-author C.A. and R.J.L. are employed by AstraZeneca R&D in Gothenburg, Sweden, AstraZeneca had no influence over the study. The authors declare no competing interests.

Document is current

Any future updates will be listed below